中访网数据 重庆太极实业（集团）股份有限公司于2026年2月27日召开了2026年第一次临时股东会。会 议审议并通过了两项重要议案。第一项为《关于预计公司2026年度日常关联交易额度的议案》，该议案 获得通过，其中关联股东太极集团有限公司等合计持有的约1.66亿股在表决时依法进行了回避。第二项 为《关于公司实际控制人延期履行同业竞争承诺的议案》，该议案亦获得通过。 本次股东会由董事长俞敏主持，公司部分董事及高级管理人员列席会议。出席会议的股东及代理人共计 1,237人，代表有表决权的股份总数约8,936.51万股，占公司有表决权股份总数的23.1910%。会议的召 集、召开及表决程序符合《公司法》及《公司章程》的规定，泰和泰（重庆）律师事务所律师对会议进 行了见证并出具了法律意见，认为本次股东会决议合法有效。两项议案的通过，明确了公司新一年度的 部分关联交易框架，并对解决历史遗留的同业竞争问题安排了新的时间表。 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-009 重庆太极实业（集团）股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 1,237 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 89,365,094 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 23.1910 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由董事会召集，董事长俞敏先生主持，本次会议的召集、召开及 表决方式均符合《公司法》及《公司章程》的有关规定。 (五) 公司董事和董事会秘书的列席情况 1、公司在任董事13人，列席13人； 1 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 股东会召开的时间：2026 年 2 月 27 日 (二) 股东会召开的地点：重庆市两江新区恒山东路 18 号公司 1 ...

泰和泰（重庆）律师事务所 关于 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会 之 法律意见书 中国 • 重庆市两江新区财富大道 1 号财富金融中心 36 层 36/F, Fortune Financial Center, No. 1 Fortune Avenue Liangjiang New Area, Chongqing, People's Republic of China 电话| TEL: 86-23-67887666 www.tahota.com 本法律意见书仅供本次股东会之目的使用，本所及本所律师同 意本法律意见书随同公司本次股东会决议及其他信息披露资料一并 公告。 本法律意见书仅就本次股东会的召集、召开程序、出席本次股东 会的人员资格、召集人资格、会议表决程序及表决结果是否符合《公 司法》《股东会规则》等现行有效的法律、行政法规和其他规范性文 件以及《公司章程》的规定发表意见，并不对审议的议案内容以及议 案所表述的事实或数据的真实性、合法性及准确性发表意见。 鉴于此，本所律师根据上述法律、行政法规及规范性文件的要求， 按照律师行业公认的业务标准、道德规范和勤勉尽责精神，现出具如 ...

作者 张烨静 /// 集采的车轮碾过，十年增长神话褪色，如何找到新的平衡点和生长节奏？ 中药细分赛道龙头，遭遇十年首亏！ 1月27日，中国中药发布一份"罕见"的盈利预警公告。2025年度，公司预计将由盈转亏，亏损额介于3.5 亿至5亿元，净利润同比暴跌1785%至2507%。即便剔除商誉减值等因素，利润仍同比下降45%至55%， 主营业务盈利能力几近腰斩。 过去十年以来，中国中药得益于中药配方颗粒政策红利与高成长性，从未出现亏损，2017年至2021年其 营收复合年增长率更是高达22.95% 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：E药经理人 而如今这份亏损预警似乎正式宣告：中药龙头们过去的成长与估值逻辑，正在被动摇。 ▲中国中药上市以来股价走向 配方颗粒，繁华破灭 ❤️关注我，不迷路 中国中药是中药配方颗粒的"龙头老大"，自1992年起步发展，目前在等级医疗机构的覆盖率超60%，市 场占有率53%。 作为业绩"压舱石"，中药配方颗粒板块业务占中国中药总营收的近一半。但近两年，该板块业绩屡屡下 滑。2024年营业额约为69.7亿元，同比下降23.5%。2025年上半年营 ...

Core Insights - The company focuses on the core goal of "Digital Taiji" and is advancing the integration of four key areas: business digitization, data interoperability, process intelligence, and ecological platformization [2] Group 1: Digital Transformation Initiatives - The company is implementing a comprehensive digital upgrade across marketing, production, and research sectors [2] - Data governance and AI development have achieved core data integration and visualization platform optimization [2] - Innovative applications such as AI agents have been successfully implemented [2] Group 2: Industry Impact - The modern Chinese medicine industry is being transformed into a smart and standardized model driven by data [2] - The company is leading the digitalization of the entire industry chain [2]

重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会资料 2026 年 2 月 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 目录 一、关于预计公司2026年度日常关联交易额度的议案.................3 二、关于公司实际控制人延期履行同业竞争承诺的议案.....7 1 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会议程 重庆太极实业（集团）股份有限公司 2026 年 2 月 27 日 2 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 三、到会股东审议如下议案： 1.关于预计公司 2026 年度日常关联交易额度的议案； 2.关于公司实际控制人延期履行同业竞争承诺的议案。 四、会议讨论； 五、股东及其委托代理人对相关议案投票表决； 六、表决统计； 七、见证律师宣读法律意见书； 八、到会董事在会议决议上签字； 九、主持人宣布会议结束。 重庆太极实业（集团）股份有限公司 2026 年第一次临时股 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in Chongqing, with a total of 7,966 enterprises reported for the year 2025, reflecting a slight increase of 0.09% year-on-year, which accounts for 1.52% of the national total [1][1][1] Group 2 - The report cites that the threshold for scale industrial enterprises in Chongqing was raised from an annual main business income of 5 million to 20 million yuan starting in 2011 [1] - The data source for the statistics includes the National Bureau of Statistics and is organized by Zhiyan Consulting, a leading industry consulting firm in China [1][1]

Investment Rating - The report upgrades the investment rating for the pharmaceutical and biotechnology industry to "Recommended" [1][42]. Core Insights - The pharmaceutical sector has shown resilience, with a year-to-date return of 3.28%, outperforming the Shanghai Composite Index by 2.99 percentage points [9][23]. - The report highlights the continuous support from policies, particularly for the traditional Chinese medicine (TCM) sector, which is expected to see significant growth due to government initiatives aimed at enhancing the industry [15][17]. - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that domestic companies are gradually improving their innovation capabilities [42]. Summary by Sections Recent Performance - The Shanghai Composite Index fell by 1.33% while the pharmaceutical sector rose by 0.14%, ranking 15th among 31 primary sub-industries [14][23]. - Within the pharmaceutical sub-sectors, traditional Chinese medicine, medical services, and other segments showed varying performance, with traditional Chinese medicine increasing by 2.56% [14][23]. Policy Developments - On February 5, 2026, the Ministry of Industry and Information Technology and other departments released the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)," focusing on enhancing the resilience and stability of the TCM supply chain [15][17]. - The plan aims to improve the quality and stable supply of TCM materials and products, which is crucial for the long-term development of the industry [15][17]. Market Dynamics - The report notes that the TCM sector is expected to experience a recovery in performance starting from mid-2025, with improved financial results anticipated in 2026 [9][17]. - The comprehensive index for TCM materials has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies in 2026 [9][17]. Valuation Metrics - As of February 6, 2026, the pharmaceutical sector's valuation stands at 33.3 times PE, with a premium of 32% compared to the overall A-share market (excluding financials) [24]. - The TTM valuation is at 29.4 times PE, below the historical average of 34.9 times PE, indicating potential for growth [24]. Key Companies to Watch - The report suggests focusing on companies such as Aidi Pharmaceutical, Huadong Medicine, Kangnuo Pharmaceutical-B, and others, which are positioned well within the TCM sector and are expected to benefit from policy support and market dynamics [35][43].

Group 1 - The core point of the article is that Taiji Group (600129) announced a plan to optimize its equity structure by acquiring a 90% stake in Tongjun Pavilion Chinese Medicine Wholesale for 21.08 million yuan and a 10% stake for 2.35 million yuan from its subsidiaries [1] - The share transfer is between the company and its controlling subsidiaries, meaning it does not involve external shareholders [1] - The announcement states that the share transfer will not change the scope of the company's consolidated financial statements and will not adversely affect the company's financial and operational status [1]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].